Bronchial artery chemoembolization with apatinib for treatment of central lung squamous cell carcinoma

医学 阿帕蒂尼 不利影响 内科学 阶段(地层学) 进行性疾病 胃肠病学 栓塞 外科 总体生存率 疾病 生物 古生物学
作者
Guohui Xu,Jun Zhu,Xiaoqian Xu,Yaoyong Chen,Qiang Wang,Quanji Yue,Kaijian Lei,Yuming Jia,Guo Xiao
出处
期刊:Journal of Cancer Research and Therapeutics [BioMed Central]
卷期号:18 (5): 1432-1432 被引量:4
标识
DOI:10.4103/jcrt.jcrt_2401_21
摘要

To evaluation the clinical efficacy and safety of bronchial artery chemoembolization (BACE) combined with apatinib for treatment of advanced central lung squamous cell carcinoma (LSCC).Forty-seven patients with pathologically diagnosed stage IIIB or IV central LSCC that was not resectable were selected among hospital patients presenting after November 2016. Twenty-one patients were treated with BACE combined with apatinib; the remaining patients served as a control group treated with BACE alone. Objective response rate (ORR) and disease control rate (DCR) were evaluated with postoperative contrast-enhanced CT scans at 3, 6, and 12 months. Progression-free survival (PFS) curves were used to evaluate curative effects. Adverse events were recorded to assess safety.BACE operations were successfully completed in all 47 patients. Significant differences were found at six and 12 months (P < 0.05). Median PFS was 322 days in the observation group and 209 days in the control group: a statistically significant difference (P = 0.042). One-year survival rates were 76.19% and 46.15% for observation and control patients, respectively; this difference was also significant (P = 0.037). Three patients in the observation group received emergency interventional embolization for hemoptysis, and patients with grade III or greater adverse reaction events (AE) accounted for 19.05% of patients (4/21); these subjects improved or were controlled after active treatment.BACE combined with apatinib is effective for treatment of advanced central LSCC, with definite short-term efficacy, controllable risk, and high safety. Investigation with a larger sample size is warranted to confirm study results.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ElbingX发布了新的文献求助20
刚刚
刚刚
刚刚
Zz发布了新的文献求助10
刚刚
笑靥如花发布了新的文献求助10
刚刚
董晓坤完成签到,获得积分10
2秒前
彭于晏应助hvivi6采纳,获得10
2秒前
3秒前
4秒前
yyyyyy完成签到 ,获得积分10
4秒前
5秒前
貔貅完成签到,获得积分10
5秒前
DD立芬完成签到 ,获得积分10
6秒前
7秒前
7秒前
敬老院N号应助南宫映榕采纳,获得30
7秒前
7秒前
YY发布了新的文献求助10
7秒前
梁洛嘉关注了科研通微信公众号
8秒前
GAO完成签到,获得积分10
8秒前
旧戏人发布了新的文献求助10
8秒前
8秒前
9秒前
9秒前
10秒前
邢文瑞发布了新的文献求助10
10秒前
mmz666完成签到,获得积分10
11秒前
11秒前
xiao发布了新的文献求助10
12秒前
sheila完成签到,获得积分10
14秒前
YY完成签到,获得积分10
14秒前
mmz666发布了新的文献求助10
14秒前
酷波er应助PEI采纳,获得10
15秒前
16秒前
发文章鸭完成签到 ,获得积分10
16秒前
andrele发布了新的文献求助30
16秒前
16秒前
王有闲发布了新的文献求助10
16秒前
CipherSage应助艺玲采纳,获得10
16秒前
17秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976177
求助须知:如何正确求助?哪些是违规求助? 3520366
关于积分的说明 11202745
捐赠科研通 3256847
什么是DOI,文献DOI怎么找? 1798509
邀请新用户注册赠送积分活动 877704
科研通“疑难数据库(出版商)”最低求助积分说明 806516